Get the Stockscreener App
0.00
100.00%
-46.99
After Hours:
46.98
46.98
+
Springworks Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
See More
Previous Close:
$46.99
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$3.52B
Revenue:
-
Net Income/Loss:
$-275.16M
P/E Ratio:
0.00
EPS:
-3.89
Net Cash Flow:
$-221.15M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$62.00
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Name
Springworks Therapeutics Inc
Sector
Industry
Phone
203-883-9490
Address
100 WASHINGTON BOULEVARD, STAMFORD, CT
Compare SWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
0.00 | 3.52B | 0 | -275.16M | -221.15M | -3.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Initiated | Evercore ISI | Outperform |
| Feb-05-24 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| Mar-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-04-19 | Initiated | H.C. Wainwright | Buy |
| Oct-08-19 | Initiated | Cowen | Outperform |
| Oct-08-19 | Initiated | Goldman | Buy |
| Oct-08-19 | Initiated | JP Morgan | Overweight |
| Oct-08-19 | Initiated | Wedbush | Outperform |
View All
Springworks Therapeutics Inc Stock (SWTX) Latest News
What institutional investors are buying SpringWorks Therapeutics Inc. stockBeginner Investor Tips With Low Risk - jammulinksnews.com
How volatile is SpringWorks Therapeutics Inc. stock compared to the marketEarnings Report Opportunities To Watch Now - jammulinksnews.com
Should I hold or sell SpringWorks Therapeutics Inc. stock in 2025Value Investing Data Feed For Beginners - jammulinksnews.com
What catalysts could drive SpringWorks Therapeutics Inc. stock higher in 2025Stock Market Recommendation With Low Risk - jammulinksnews.com
Published on: 2025-07-30 08:30:59 - metal.it
Published on: 2025-07-29 02:19:36 - beatles.ru
Sentiment Tools Show Shift in Trader Mood on SpringWorks Therapeutics Inc.Conservative Entry for High Return Setup Backed - metal.it
What makes SpringWorks Therapeutics Inc. stock price move sharplyEarly Breakout Entry Point Notifications Sent - metal.it
Is SpringWorks Therapeutics Inc. a growth stock or a value stockUnlock exclusive stock market forecasts - jammulinksnews.com
What are SpringWorks Therapeutics Inc. company’s key revenue driversAchieve breakthrough investment performance - jammulinksnews.com
Is SpringWorks Therapeutics Inc. stock overvalued or undervaluedFree Market Volatility Navigation Tips - jammulinksnews.com
Why SpringWorks Therapeutics Inc. stock attracts strong analyst attentionEarly Breakout Tracker - metal.it
What drives SpringWorks Therapeutics Inc. stock priceDynamic portfolio growth - Autocar Professional
Is SpringWorks Therapeutics Inc. a good long term investmentFree Market Volatility Navigation Tips - PrintWeekIndia
What analysts say about SpringWorks Therapeutics Inc. stockFree Investment Community - PrintWeekIndia
SpringWorks Therapeutics Inc. Stock Analysis and ForecastConsistent wealth multiplication - PrintWeekIndia
Neurofibromatosis Type 2 Pipeline 2025: MOA and ROA Insights, - openPR.com
SpringWorks Therapeutics (SWTX) Surged on Acquisition News - MSN
European Commission Grants Conditional Approval for SpringWorks Therapeutics' EZMEKLY® to Treat Plexiform Neurofibromas in NF1 Patients - Nasdaq
European Commission Grants Conditional Approval of EZMEKLY® - GlobeNewswire
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN - Yahoo Finance
California Rep. Gilbert Ray Cisneros Sold Over $28K Worth of SpringWorks Therapeutics Inc Ordinary Shares Stock: Here's What You Should Know - Nasdaq
Principal Financial Group Inc. Decreases Stock Position in SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
CIBRA Capital Ltd Purchases New Holdings in SpringWorks Therapeutics (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics - Hartford Business Journal
Merck completes $3.4bn acquisition of SpringWorks Therapeutics - World Pharmaceutical Frontiers
Merck concludes SpringWorks acquisition for $3.4bn - Yahoo Finance
SpringWorks Therapeutics, Inc.(NasdaqGS: SWTX) dropped from S&P TMI Index - MarketScreener
SpringWorks Therapeutics Completes Merger and Delisting - TipRanks
SpringWorks Therapeutics: Unlocking Value Through Merck's EU Regulatory Milestones - AInvest
SpringWorks Therapeutics Nears EU Approval for First Desmoid Tumor Therapy, Nirogacestat - MSN
SpringWorks Trading Volume Plummets 39.55% to 472nd Rank Despite Slight Stock Price Gain - AInvest
Springworks Therapeutics Inc Stock (SWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):